Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study.

[1]  J. Januzzi,et al.  Emerging biomarkers in heart failure. , 2012, Clinical chemistry.

[2]  L. Dušek,et al.  Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry , 2011, Critical care.

[3]  S. Manzano-Fernández,et al.  Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.

[4]  M. Givertz,et al.  Novel Biomarkers in Acute Heart Failure , 2011, Current heart failure reports.

[5]  M. Kawana,et al.  Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. , 2010, American heart journal.

[6]  A. Buser,et al.  Use of myeloperoxidase for risk stratification in acute heart failure. , 2010, Clinical chemistry.

[7]  V. Hasselblad,et al.  Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. , 2010, Journal of the American College of Cardiology.

[8]  Piotr Ponikowski,et al.  Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure , 2010, European journal of heart failure.

[9]  J. Januzzi,et al.  ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure , 2010, Current heart failure reports.

[10]  T. Mueller,et al.  Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath , 2009, Heart.

[11]  F. Harrell,et al.  Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.

[12]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[13]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[14]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[15]  G. Fonarow,et al.  Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2008, Journal of the American College of Cardiology.

[16]  M. Metra,et al.  Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance , 2008, European journal of heart failure.

[17]  F. van Lente,et al.  Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. , 2008, The American journal of cardiology.

[18]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[19]  C. Phillips,et al.  Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. , 2008, The American journal of cardiology.

[20]  N. Cook.  Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. , 2008, Clinical chemistry.

[21]  D. Morrow,et al.  Benchmarks for the Assessment of Novel Cardiovascular Biomarkers , 2007, Circulation.

[22]  M. Nieminen,et al.  Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.

[23]  M. Nieminen,et al.  Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. , 2006, European heart journal.

[24]  C. Mueller,et al.  Inflammation and long-term mortality in acute congestive heart failure. , 2006, American heart journal.

[25]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[26]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[27]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[28]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[29]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[30]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[31]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[32]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.